Prometheus Biosciences, Inc., (RXDX) Social Stream



Prometheus Biosciences, Inc., (RXDX): $29.02

-0.66 (-2.22%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add RXDX to Watchlist
Sign Up

Industry: Biotech


Ranked

of NR

in industry

Prometheus Biosciences Inc (RXDX) Price Targets From Analysts

Use the tables below to see what analysts covering Prometheus Biosciences Inc think about its future price and what recommendations they have for investors and traders.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2021-11-02 3 $40 $34 $36.333 $38.81 -6.38%
2021-11-15 4 $45 $34 $38.5 $38.81 -0.8%
2021-12-08 5 $50 $40 $44.8 $38.81 15.43%
2022-01-13 6 $50 $40 $45 $38.81 15.95%
2022-02-11 7 $62 $40 $47.428 $38.81 22.21%
2022-03-10 7 $62 $40 $48.571 $38.81 25.15%

The Trend in the Analyst Price Target


Over the past 48 weeks, RXDX's average price target has gone up $16.32.

Over the past 48 weeks, RXDX's average upside potential has been 36.49%.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-06-05 NA 40 25 32.25 23.11 39.55%
2021-08-05 NA 40 30 34.67 23.80 45.67%
2021-11-15 5 45 34 38.50 34.32 12.18%
2021-12-08 5 50 40 44.80 33.50 33.73%
2021-12-08 6 50 40 44.80 33.50 33.73%

RXDX Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
1.14 6 1 0 0 0 7

The Trend in the Broker Recommendations


RXDX's average broker recommendation rating improved by 0.03 over the prior 90 days.

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for RXDX as an investment opportunity.

  • RXDX has a higher upside potential (average analyst target price relative to current price) than 74.03% of Pharmaceutical Products stocks.
  • Prometheus Biosciences Inc's average analyst price target is higher than 908.25% of stocks in the small market cap category.
  • In terms of how Prometheus Biosciences Inc fares relative to Pharmaceutical Products stocks, note that its variance in analysts' estimates is lower than -129.12% of that group.
  • Prometheus Biosciences Inc's number of analysts covering the stock is greater than 701.02% of stocks in the small market cap category.

Stocks similar to Prometheus Biosciences Inc in the Pharmaceutical Products industry regarding analyst recommendations and price targets are RPTX, RNA, and RMTI.

Is RXDX a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.6552 seconds.